

Section 4 - Biochemistry, Pharmacology and Toxicology II: 31. Jan 2024, 8:30 – 12:00

CHAIRPERSONS: ASSOC. PROF. RNDR. JAKUB HOFMAN, PH.D., ASSOC. PROF. ING. PETRA MATOUŠKOVÁ, PH.D.

8:30 - 8:45	BPT15	CHANGES IN THE EXPRESSION AND ACTIVITIES OF DETOXIFICATION ENZYMES IN THE IN VIVO MODEL OF NAFLD <i>GABRIELA SVOBODOVÁ</i>
8:45 - 9:00	BPT16	TRANSGENIC MICE OVEREXPRESSING HUMAN ENDOGLIN AS A PROPER ANIMAL MODEL TO STUDY THE IMPACT OF ENDOGLIN ON ENDOTHELIAL DYSFUNCTION AND LIVER DISORDERS <i>NILOUFAR MOHAMMADI</i>
9:00 - 9:15	BPT17	RADIOLABELED 15-MER PEPTIDES ARE MEGALIN LIGANDS IN CRISPR/CAS9-BASED CELLULAR MODEL <i>ANNA ĎURINOVÁ</i>
9:15 - 9:30	BPT18	A NEW WAY TO SIMULATE INTERNAL INTRINSICALLY DISORDERED PROTEINS: AN MD INVESTIGATION INTO P53 <i>MICHAEL BAKKER</i>
9:30 - 9:45	BPT19	EVALUATION OF NOVEL FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA <i>JAN RATAJ</i>
9:45 - 10:00	BPT20	EFFECT OF THE AURORA A TYROSINE KINASE INHIBITOR ALISERTIB ON ANTHRACYCLINE RESISTANCE IN CANCER CELLS <i>SU YATI</i>
10:00 - 10:15	BPT21	NEW MECHANISM OF ANTINEOPLASTIC ACTIVITY OF ZANUBRUTINIB VIA INHIBITION OF AKR1B10 <i>JANA ZELAZKOVA</i>
10:15 - 10:30		BREAK

CHAIRPERSONS: ASSOC. PROF. PHARMDR. MARTINA ČEČKOVÁ, PH.D., EDUARD JIRKOVSKÝ, PHARM.D., PH.D.

10:30 - 10:45	BPT22	QUANTITATIVE ANALYSIS OF GLUCOSE-RELATED GENES ACTIVATED BY RIFAMPICIN <i>BECHARA SAADE</i>
10:45 - 11:00	BPT23	MATHEMATICAL MODELING OF RIFAMPICIN METABOLISM IN PRIMARY HUMAN HEPATOCYTE SPHEROIDS <i>ELLEN TANAKA KAHIIYA</i>
11:00 - 11:15	BPT24	CHARACTERIZATION OF NOVEL CAR LIGANDS IN HEPATIC CELLS <i>MÁRIA KRUTÁKOVÁ</i>
11:15 – 11:30	BPT25	RHO-ASSOCIATED PROTEIN KINASE 1 INHIBITION IN HEPATOCYTES ATTENUATES NONALCOHOLIC STEATOHEPATITISRESENTATION <i>ESTER DOHNALKOVA</i>
11:30 – 11:45	BPT26	MODULATION OF ENDOGLIN AND SOLUBLE ENDOGLIN IN NASH: EXPLORING THE THERAPEUTIC BENEFITS OF MONOCLONAL ANTIBODY <i>SAMIRA EISSAZADEH</i>

11:45 – 12:00 **BPT27** **BRUTON'S TYROSINE KINASE INHIBITOR, EVOBRUTINIB, AS A NOVEL INHIBITOR OF ALDO-KETO REDUCTASE 1C3 IN THE FIGHT AGAINST RESISTANCE IN DAUNORUBICIN-BASED CANCER THERAPY**
LUCIE ČERMÁKOVÁ